Recent Studies from Fujian Cancer Hospital Add New Data to Carcinomas (Open-label, prospective phase 2 study to evaluate the efficacy and safety of camrelizumab combined with etoposide and cisplatin as neoadjuvant therapy in patients with...).

A recent study conducted at Fujian Cancer Hospital in China evaluated the efficacy and safety of camrelizumab, a humanized monoclonal antibody, combined with neoadjuvant chemotherapy in patients with neuroendocrine carcinoma of the cervix (NECC). The study found that the combination treatment achieved an overall response rate of 100%, with complete remission observed in 8.33% of patients and partial remission in 91.67% of patients. The treatment outperformed traditional therapies in terms of efficacy and had manageable toxicity levels. The study is ongoing and aims to assess secondary objectives such as disease control rate, progression-free survival, and overall survival. [Extracted from the article]